- Home
- GH vs DOCU Comparison
GH vs DOCU Comparison
Compare GH & DOCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GH | DOCU |
|---|---|---|
| Founded | 2011 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 13.9B |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GH | DOCU |
|---|---|---|
| Price | $94.00 | $45.33 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 20 | 17 |
| Target Price | ★ $117.80 | $81.00 |
| AVG Volume (30 Days) | 1.9M | ★ 4.9M |
| Earning Date | 05-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.74 | ★ 1311.11 |
| EPS | N/A | ★ 1.04 |
| Revenue | $982,021,000.00 | ★ $2,976,739,000.00 |
| Revenue This Year | $29.73 | $10.02 |
| Revenue Next Year | $27.71 | $6.69 |
| P/E Ratio | ★ N/A | $43.93 |
| Revenue Growth | ★ 32.88 | 7.78 |
| 52 Week Low | $34.91 | $40.16 |
| 52 Week High | $120.74 | $94.67 |
Technical Indicators
Market Signals| Indicator | GH | DOCU |
|---|---|---|
| Relative Strength Index (RSI) | 36.72 | 38.85 |
| Support Level | $54.39 | $41.53 |
| Resistance Level | $115.77 | $71.47 |
| Average True Range (ATR) | 6.12 | 2.21 |
| MACD | -1.26 | 0.67 |
| Stochastic Oscillator | 9.73 | 58.01 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About DOCU DocuSign Inc.
Docusign offers Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its initial public offering in 2018.